3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

Modern urological diagnosis relies on the precise integration of anatomical, functional, and molecular imaging modalities. Urologists must master radiation safety, contrast media pharmacodynamics, quantitative ultrasonography, multiphase computed tomography, multiparametric MRI, and nuclear renography.

---

1. Radiation Protection & Contrast Media Safety

Radiation Safety Principles

• ALARA Principle: Radiation exposure must be kept As Low As Reasonably Achievable, utilizing dose-reduction technologies such as automated tube current modulation, low-kilovoltage settings, and iterative reconstruction.
• Biological Effects:
  • Stochastic Effects: Probability of occurrence increases with dose, but severity is independent of dose. There is no threshold dose; the primary stochastic risk is radiation-induced secondary carcinogenesis. The linear no-threshold (LNT) model applies.
  • Deterministic Effects: Occur only after exceeding a specific threshold dose; severity correlates directly with dose (e.g., skin erythema threshold >2 Gy, radiation cataracts threshold >0.5 Gy).
• Dosimetry: Effective dose is quantified in milliSieverts (mSv). Natural background radiation is 2–3 mSv/year. Low-dose non-contrast stone CT delivers 1.5–3 mSv, whereas multiphase CT urography can deliver 15–25 mSv, underscoring the need for protocol optimization.

Contrast-Induced Nephropathy (CIN) & PC-AKI

• Definition: Post-Contrast Acute Kidney Injury (PC-AKI) is an absolute increase in serum creatinine ≥0.3 mg/dL (26.5 µmol/L) or a relative increase ≥50% over baseline within 48 to 72 hours following intravascular iodinated contrast administration.
• Risk Stratification: Pre-existing severe renal impairment is the primary risk factor. Patients with eGFR <30 mL/min/1.73 m² undergoing intravenous contrast (or eGFR <45 mL/min/1.73 m² undergoing intra-arterial contrast with first-pass renal exposure) are at significant risk.
• Prevention: ESUR recommends intravenous hydration for at-risk patients; isotonic saline and sodium bicarbonate have similar efficacy. One saline regimen is 1 mL/kg/h for 3–4 hours before and 4–6 hours after contrast. Individualize fluids in severe heart failure or end-stage renal disease. Oral fluids alone are insufficient; no drug prophylaxis has consistent proven benefit.
• Metformin Management: Withhold at contrast administration if there is AKI, eGFR <30 mL/min/1.73 m², or intra-arterial first-pass renal exposure. Reassess renal function within 48 hours and restart if stable. With eGFR >30 and no AKI, metformin can continue for intravenous or intra-arterial second-pass exposure. The concern is accumulation if renal function deteriorates, causing lactic acidosis.

Nephrogenic Systemic Fibrosis (NSF)

• Pathophysiology: Nephrogenic Systemic Fibrosis is a debilitating, fibrosing multisystem disorder affecting the skin, subcutaneous tissues, and internal organs (lungs, myocardium). It is triggered by the release and tissue accumulation of free, toxic gadolinium ions (Gd3+) following the administration of gadolinium-based contrast agents (GBCAs) to patients with severe acute or chronic kidney disease (eGFR <15–30 mL/min/1.73 m² or on dialysis).
• Agent Classification:
  • High-Risk Linear Chelates: Linear non-ionic agents (e.g., gadodiamide [Omniscan], gadoversetamide). These possess lower thermodynamic stability, permitting spontaneous dechelation and dissociation of free gadolinium. They are strictly contraindicated in severe renal disease.
  • Low/Negligible-Risk Macrocyclic Chelates: Macrocyclic agents (e.g., gadoterate meglumine [Dotarem], gadobutrol [Gadovist], gadoteridol [ProHance]). The macrocyclic ring structure cages the gadolinium ion with extraordinary thermodynamic and kinetic stability, resulting in virtually zero documented cases of NSF. Macrocyclic agents represent the standard of care.

---

2. Renal & Scrotal Ultrasonography

Grayscale Renal Parenchymal Assessment

• Echogenicity: Normal renal cortical echogenicity is isoechoic or slightly hypoechoic relative to normal liver parenchyma (right kidney) and spleen (left kidney). The renal pyramids (medulla) are distinctly hypoechoic. Increased cortical echogenicity exceeding liver echogenicity indicates medical renal disease (glomerulonephritis, diabetic nephropathy, hypertensive nephrosclerosis).
• Parenchymal Thickness: Normal renal parenchymal thickness is 1.5 to 2.0 cm.

Hydronephrosis Grading (Society for Fetal Urology - SFU Classification)

Spectral Doppler: The Resistive Index in Acute Obstruction

• Formula: The Resistive Index (RI) is calculated from spectral Doppler waveforms of interlobar or arcuate arteries:

  $\text{RI} = \frac{\text{Peak Systolic Velocity (PSV)} - \text{End Diastolic Velocity (EDV)}}{\text{Peak Systolic Velocity (PSV)}}$

  Simplified: RI = (PSV - EDV) / PSV.

• Diagnostic Cutoffs: Normal renal RI is 0.58 to 0.65 (upper limit of normal <0.70).

• Acute Obstruction: Increased intrarenal vascular resistance may reduce end-diastolic flow. RI >0.70, or a side-to-side ΔRI ≥0.08–0.10, can support acute unilateral obstruction. RI is an adjunct: neither an elevated value confirms obstruction nor a normal value excludes it. Interpret Doppler with collecting-system anatomy, symptoms and other imaging.

Testicular Color Doppler: Torsion vs. Epididymo-Orchitis

• Spermatic Cord Torsion: Surgical emergency. Findings include absence or significant reduction of intratesticular color and spectral Doppler flow, an enlarged and hypoechoic/heterogeneous testis (indicating ischemic infarction), and the "whirlpool sign" of a twisted spermatic cord. Persistent arterial flow does not exclude early or partial torsion. If clinical suspicion is high, immediate surgical exploration must not be delayed for ultrasound.
• Acute Epididymo-Orchitis: Characterized by marked hypervascularity on color Doppler ("firestorm pattern"), low-resistance spectral Doppler waveforms, enlarged and hypoechoic epididymal tail/head and testis, thickened scrotal wall, and reactive inflammatory hydrocele.

---

3. Computed Tomography Urography (CTU) & HU Attenuation

CT urography is the gold standard imaging modality for evaluating hematuria, renal cortical masses, and upper tract urothelial carcinoma (UTUC).

Multiphase Protocol Sequences

1. Unenhanced (Non-Contrast) Phase: Crucial for detecting radio-opaque urinary calculi, assessing baseline attenuation of renal masses, and identifying macroscopic fat or acute hemorrhage.
2. Corticomedullary Phase (25–40 seconds post-injection): Demonstrates intense enhancement of the renal cortex while the medulla remains unenhanced. Optimal for visualizing renal vascular anatomy (renal artery stenosis, pseudoaneurysms, renal vein thrombus).
3. Nephrographic Phase (80–120 seconds post-injection): The renal cortex and medulla enhance uniformly. This is the single most sensitive and accurate phase for detecting, characterizing, and delineating renal cortical neoplasms and medullary extensions.
4. Excretory (Delayed) Phase (5–15 minutes post-injection): Dense opacification of the pelvicalyceal system, ureters, and bladder lumen. Essential for identifying urothelial filling defects, UTUC, and ureteral strictures.

Quantitative Hounsfield Unit (HU) Characterization

• Simple Renal Cyst (Bosniak Category I): Homogeneous water attenuation (-10 to +20 HU), imperceptible wall, no internal septations, and no enhancement (<10 HU increase post-contrast).
• Angiomyolipoma (AML): Characterized by the presence of macroscopic fat, defined by attenuation values ≤ -20 HU (typically -40 to -80 HU). Demonstration of fat density within a solid renal mass without calcification is pathognomonic for AML.
• Renal Cell Carcinoma (RCC): Solid soft-tissue mass exhibiting significant contrast enhancement: an increase in attenuation of ≥15 to 20 HU between the unenhanced phase and the nephrographic/corticomedullary phase confirms vascular enhancement diagnostic of neoplasm.
• Hyperattenuating Cyst (Bosniak Category II): Homogeneous, benign hyperattenuating cysts include those measuring ≥70 HU on unenhanced CT, or >20 HU and non-enhancing on a renal-mass CT protocol. Assess the wall, septa and nodules before classification; protein or blood can raise attenuation without indicating malignancy.

---

4. Multiparametric MRI (mpMRI) & PI-RADS v2.1

Multiparametric MRI is the cornerstone of prostate cancer diagnosis, risk stratification, and targeted biopsy guidance.

Sequence Dynamics & Zonal Anatomy

• T2-Weighted (T2W) Imaging: Provides high-resolution anatomical differentiation. Normal peripheral zone tissue is hyperintense (bright) on T2W; clinically significant cancers appear as hypointense (dark) focal lesions. T2W is the dominant sequence for the Transition Zone (TZ).
• Diffusion-Weighted Imaging (DWI) & Apparent Diffusion Coefficient (ADC): Evaluates the Brownian motion of water molecules. Densely packed malignant cells restrict water diffusion. Clinically significant prostate cancer demonstrates focal restricted diffusion: hyperintense on high b-value images (b ≥ 1400 s/mm²) and markedly hypointense on ADC maps. DWI/ADC is the dominant sequence for the Peripheral Zone (PZ).
• Dynamic Contrast-Enhanced (DCE) Imaging: Rapid gadolinium bolus assessing microvascular permeability and neoangiogenesis. Positive DCE is focal enhancement earlier than or contemporaneous with adjacent normal tissue, matching a suspicious T2W/DWI lesion; rapid washout is not required. In PI-RADS v2.1, DCE functions exclusively as a secondary tiebreaker for Category 3 lesions in the peripheral zone.

PI-RADS v2.1 Scoring Mechanics

• Peripheral Zone (PZ) Rule:
  • Determined primarily by DWI/ADC score.
  • A DWI score of 3 is upgraded to PI-RADS 4 if DCE is positive (focal, early enhancement).
  • If DCE is negative, the lesion remains PI-RADS 3.
• Transition Zone (TZ) Rule:
  • Determined primarily by T2W score.
  • T2W 2 with DWI ≥4 becomes PI-RADS 3.
  • T2W 3 with DWI 5 becomes PI-RADS 4; with DWI ≤4 it remains PI-RADS 3.
• Clinical Score Interpretation:
  • PI-RADS 1: Clinically significant cancer highly unlikely;
  • PI-RADS 2: Clinically significant cancer unlikely;
  • PI-RADS 3: Clinically significant cancer equivocal;
  • PI-RADS 4: Clinically significant cancer is likely (targeted biopsy indicated);
  • PI-RADS 5: Clinically significant cancer highly likely (lesion ≥ 1.5 cm, definite extraprostatic extension, or neurovascular invasion; targeted biopsy indicated).

---

5. Nuclear Medicine in Urology

99mTc-MAG3 Diuretic Renography

• Tracer Kinetics: 99mTc-Mercaptoacetyltriglycine (MAG3) is cleared 95% by active proximal tubular secretion with high first-pass extraction (~40%–50%). It reflects Effective Renal Plasma Flow (ERPF). It is superior to 99mTc-DTPA (which is cleared purely by glomerular filtration) in patients with impaired renal function, hydronephrosis, or pediatric uropathies.
• Furosemide Washout Renography: Differentiates mechanical pelviureteric junction obstruction (PUJO) from non-obstructive residual collecting system dilatation. Intravenous furosemide (0.5–1.0 mg/kg) is administered either 20 minutes after tracer injection (F+20) or simultaneously (F-0).
• Clearance Half-Time (T1/2) Interpretation:
  • T1/2 < 10 minutes: Normal washout; no mechanical obstruction;
  • T1/2 = 10 to 20 minutes: Equivocal / indeterminate;
  • T1/2 > 20 minutes: Delayed washout, suspicious for obstruction but not diagnostic alone. Review hydration, bladder emptying, the full curve, cortical transit and post-void/upright drainage, together with symptoms and serial differential function.

99mTc-DMSA Cortical Scintigraphy

• Mechanism: 99mTc-Dimercaptosuccinic acid (DMSA) is retained in renal cortical proximal tubular tissue. Approximately 40%–50% of the dose remains fixed in the renal cortex at 2 to 4 hours post-injection, with minimal urinary excretion.
• Clinical Indications:
  • Split Renal Function (Differential Function): Gold standard for quantifying percentage contribution of each kidney (normal split function: 45% to 55% per kidney). Very low differential function informs counselling, but does not by itself establish irreversibility or require nephrectomy. In children, integrate symptoms, serial function and anatomy when discussing reconstruction, observation or nephrectomy.
  • Cortical Scarring: Gold standard for detecting focal parenchymal defects/scars resulting from recurrent acute pyelonephritis or high-grade vesicoureteral reflux (VUR) in children.

PSMA-PET/CT (68Ga-PSMA / 18F-DCFPyL)

• Target Biology: Prostate-Specific Membrane Antigen (PSMA) is a 750-amino-acid type II transmembrane glycoprotein exhibiting carboxypeptidase and folate hydrolase activity. PSMA expression is upregulated 100- to 1000-fold in prostate adenocarcinoma cells compared to normal prostatic tissue, with expression density correlating with high Gleason grade, metastatic spread, and castration resistance.
• Radiotracers: 68Ga-PSMA-11, 18F-DCFPyL, and 18F-PSMA-1007.
• Landmark proPSMA Trial Evidence: In men with high-risk features undergoing primary staging, PSMA-PET/CT demonstrated 27% higher absolute accuracy than conventional imaging (CT plus 99mTc bone scan) (92% vs. 65%, p < 0.0001), with superior sensitivity (85% vs. 38%) and fewer equivocal findings.
• Biochemical Recurrence (BCR): After prostatectomy, EAU recommends PSMA-PET/CT at PSA >0.2 ng/mL if the result will influence treatment. After radiotherapy, use it in patients fit for curative salvage treatment, with MRI to guide local biopsy. Detection increases with PSA and is possible below 0.5 ng/mL; a negative scan does not exclude microscopic recurrence.

---

Comparison of Core Urological Imaging Modalities